Yueyue Chen

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer.

Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: November 01, 2025

Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer.

Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer.

Journal: Cancer cell

Published: September 16, 2025

m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis.

m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis.

Journal: Cell death & disease

Published: April 23, 2025

Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer.

Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer.

Journal: Nature communications

Published: February 18, 2025

Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing.

Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing.

Journal: Discover oncology

Published: December 02, 2024

Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism.

Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism.

Journal: Gastroenterology

Published: November 11, 2024

Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis.

Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis.

Journal: Cell reports. Medicine

Published: January 30, 2024

Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer.

Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer.

Journal: Cancer cell

Published: August 15, 2023

The diverse pancreatic tumor cell-intrinsic response to IFNγ is determined by epigenetic heterogeneity.

The diverse pancreatic tumor cell-intrinsic response to IFNγ is determined by epigenetic heterogeneity.

Journal: Cancer letters

Published: January 02, 2023

Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.

Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 18, 2022

Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer.

Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer.

Journal: Biochemical and biophysical research communications

Published: April 30, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026